Race Communications Kicks Off Madera Construction, Rolling Out All-Fiber Infrastructure BeyondSpring Provides Business Update and Reports Year End 2022 Financial Results
– SEED Therapeutics, a BeyondSpring Subsidiary, Achieved Milestones on the Eli Lilly Collaboration – BeyondSpring…
BeyondSpring Provides Business Update and Reports Year End 2022 Financial Results
– SEED Therapeutics, a BeyondSpring Subsidiary, Achieved Milestones on the Eli Lilly Collaboration – BeyondSpring…
OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare
Fisher Healthcare, a part of Thermo Fisher Scientific, will become the non-exclusive national laboratory distribution…
OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare
Fisher Healthcare, a part of Thermo Fisher Scientific, will become the non-exclusive national laboratory distribution…
Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting
BOSTON, April 18, 2023 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced highlights…
Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting
BOSTON, April 18, 2023 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced highlights…
BeyondSpring Files 2022 Annual Report on Form 20-F
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) — BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI),…
BeyondSpring Files 2022 Annual Report on Form 20-F
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) — BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI),…
ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals,…
ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals,…
Plus Therapeutics to Participate in Panel at the Canaccord Genuity Horizons in Oncology Virtual Conference
AUSTIN, Texas, April 18, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”),…
Plus Therapeutics to Participate in Panel at the Canaccord Genuity Horizons in Oncology Virtual Conference
AUSTIN, Texas, April 18, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”),…
Tilray Brands Ranks on the Brewers Association List of Top Producing Craft Brewers in the United States
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY),…
Tilray Brands Ranks on the Brewers Association List of Top Producing Craft Brewers in the United States
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY),…
GENFIT Announces Publication of the 2022 Universal Registration Document and the 2022 Annual Report on Form 20-F
Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 18, 2023 – GENFIT (Nasdaq and…
GENFIT Announces Publication of the 2022 Universal Registration Document and the 2022 Annual Report on Form 20-F
Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 18, 2023 – GENFIT (Nasdaq and…
Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023
BOSTON, April 18, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company…
Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023
BOSTON, April 18, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company…
Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting
● ZW191 demonstrates strong responses in FRα-low expressing patient-derived xenograft (PDX) models with favorable pharmacokinetic…
Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting
● ZW191 demonstrates strong responses in FRα-low expressing patient-derived xenograft (PDX) models with favorable pharmacokinetic…